CA2382425A1 - Mutants d'interferon tau et leurs techniques de preparation - Google Patents

Mutants d'interferon tau et leurs techniques de preparation Download PDF

Info

Publication number
CA2382425A1
CA2382425A1 CA002382425A CA2382425A CA2382425A1 CA 2382425 A1 CA2382425 A1 CA 2382425A1 CA 002382425 A CA002382425 A CA 002382425A CA 2382425 A CA2382425 A CA 2382425A CA 2382425 A1 CA2382425 A1 CA 2382425A1
Authority
CA
Canada
Prior art keywords
ifn
protein
tau
leu
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002382425A
Other languages
English (en)
Inventor
Carol H. Pontzer
Lynnette H. Shorts
Christina Dancz Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2382425A1 publication Critical patent/CA2382425A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne le domaine de la santé humaine et animale, et plus particulièrement les usages pharmacologiques d'analogues ou de mutants de l'interféron-tau (IFN-.tau.) qui diffère de l'IFN-.tau. natif, du fait des substitutions d'acides aminés proches de la terminaison amino de la molécule d'IFN-.tau. qui assure une activité biologique améliorée. Les mutants d'IFN-.tau. décrits possèdent une faible toxicité, présentent la même activité antivirale que le très efficace IFN-alpha ou une activité légèrement réduite par rapport à celui-ci, et développent une activité antiproliférative accrue par rapport à l'activité de l'IFN-tau natif, ce qui les rend utiles pour traiter les infections virales, le cancer, et les maladies du système immunitaire notamment les maladies auto-immunes. L'invention concerne également une technique permettant de préparer de nouvelles protéines de recombinaiso, en particulier des interférons, des interleukines, des cytokines, des hormones polypeptides et d'autres produits biopharmaceutiques possédant une activité biologique améliorée sur les protéines connues, et/ou une faible toxicité, et/ou une stabilité accrue.
CA002382425A 1999-06-22 2000-06-22 Mutants d'interferon tau et leurs techniques de preparation Abandoned CA2382425A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14041199P 1999-06-22 1999-06-22
US60/140,411 1999-06-22
PCT/IB2000/001080 WO2000078266A2 (fr) 1999-06-22 2000-06-22 Mutants d'interferon tau et leurs techniques de preparation

Publications (1)

Publication Number Publication Date
CA2382425A1 true CA2382425A1 (fr) 2000-12-28

Family

ID=22491109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002382425A Abandoned CA2382425A1 (fr) 1999-06-22 2000-06-22 Mutants d'interferon tau et leurs techniques de preparation

Country Status (5)

Country Link
EP (1) EP1156771A2 (fr)
JP (1) JP2003525592A (fr)
AU (1) AU6175800A (fr)
CA (1) CA2382425A1 (fr)
WO (1) WO2000078266A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213597A (ja) 2000-07-19 2006-08-17 Pepgen Corp インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法
AU2001277055A1 (en) * 2000-07-19 2002-01-30 Pepgen Corporation Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
US7083782B2 (en) 2000-07-19 2006-08-01 Pepgen Corporation Method of treatment using interferon-tau
US7105154B2 (en) 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
WO2007018846A2 (fr) * 2005-07-27 2007-02-15 Pepgen Coporation Procedes permettant de reduire la formation de tissus cicatriciels
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
FR2905375A1 (fr) * 2006-08-29 2008-03-07 Biomethodes Sa Variants ameliores de l'interferon alpha humain
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN108840921B (zh) * 2018-05-31 2021-06-29 浙江善测禾骑士生物科技有限公司 羊α干扰素突变体及其制备方法和应用
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека
US20230131808A1 (en) * 2020-04-22 2023-04-27 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
TW391983B (en) * 1992-10-30 2000-06-01 Univ Florida Human interferon TAU, processes thereof and pharmaceutical uses thereof

Also Published As

Publication number Publication date
AU6175800A (en) 2001-01-09
EP1156771A2 (fr) 2001-11-28
WO2000078266A2 (fr) 2000-12-28
JP2003525592A (ja) 2003-09-02
WO2000078266A3 (fr) 2001-08-23

Similar Documents

Publication Publication Date Title
US6833256B1 (en) Interferon tau mutants and methods for making them
KR100630849B1 (ko) 인터페론 베타-1ａ의 중합체 접합체 및 용도
US7504237B2 (en) Polynucleotides encoding interferon gamma polypeptides
EP1121382B9 (fr) Proteines de fusion a interferon beta et leurs utilisations
JP6325585B2 (ja) インターロイキン−２２のウイルス性肝炎の治療における応用
JP2004534523A (ja) 新規なインターフェロンβ様分子
JP2003519478A (ja) Ｇ−ｃｓｆ結合体
JP2004522803A (ja) インターフェロン製剤
EP3028713A1 (fr) Utilisation de g-csf dimèrique dans le traitement de la neutropénie
CA2382425A1 (fr) Mutants d'interferon tau et leurs techniques de preparation
CA2572751A1 (fr) Peg-interferon alpha-1b
Tian et al. Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon α1 fusion protein expressed in Pichia pastoris
CN101111519A (zh) 人β干扰素突变蛋白
KR20030094336A (ko) 인터페론 감마 폴리펩티드 변이체
US20030017550A1 (en) DNA sequences encoding fusion proteins comprising IFN-beta and TM-alpha1
RU2268749C2 (ru) КОНЪЮГАТЫ γ-ИНТЕРФЕРОНА
AU1270101A (en) Interferon gamma conjugates
AU2002235727A1 (en) New interferon beta-like molecules

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead